Table 1.
Clinical characteristics of female and male SLE remission patients and healthy controls
| Women | Men | |||
|---|---|---|---|---|
| Healthy controls | SLE remission patients | Healthy controls | SLE remission patients | |
| n = 150 | n = 83 | n = 150 | n = 22 | |
| Age (years) | 45 ± 16 | 45 ± 14 | 44 ± 16 | 52 ± 14 |
| Time since initial diagnosis (months) | 185 ± 112 | 132 ± 97 | ||
| Renal involvement, n (%) | 64 (77%) | 17 (77%) | ||
| SLEDAI | 2 ± 2 | 1 ± 1 | ||
| ANA titer ≤ 1:1280, n (%) | 43 (52%) | 11 (50%) | ||
| DsDNA antibodies ELISA (IU/ml) | 66 ± 161 | 21 ± 16 | ||
| C3 complement (g/l) | 1.1 ± 0.2 | 1.2 ± 0.2 | ||
| C4 complement (g/l) | 0.2 ± 0.1 | 0.2 ± 0.1 | ||
| Erythrocyturia (x μl−1) | 25 ± 119 | 6 ± 11 | ||
| Leukocyturia (× μl−1) | 18 ± 76 | 9 ± 23 | ||
| Serum leucocytes (× nl−1) | 7 ± 3 | 7 ± 2 | ||
| Serum creatinine (mg dl−1) | 0.9 ± 0.6 | 1.2 ± 1.0 | ||
| CKD-EPI GFR (ml min−1 (1.73 m2)−1) | 92 ± 32 | 89 ± 30 | ||
| Urine-Protein/Urine-creatinine Ratio (g (mol creatinine)−1) | 63 ± 120 | 54 ± 90 | ||
| Medication | ||||
| No Medication, n (%) | 2 (2%) | 1 (5%) | ||
| Antimalarials, n (%) | 65 (78%) | 15 (68%) | ||
| Mycophenolic acid (MPA), n (%) | 33 (40%) | 10 (45%) | ||
| Azathioprine (AZA), n (%) | 20 (24%) | 2 (9%) | ||
| Glucocorticoids, n (%) | 49 (59%) | 12 (55%) | ||
| Glucocorticoid dose (mg d−1) | 7 ± 8 | 9 ± 15 | ||
ANA antinuclear antibodies; CKD-EPI GFR chronic kidney disease epidemiology collaboration estimated glomerular filtration rate; DsDNA antibodies ELISA double-stranded DNA antibodies enzyme-linked immunosorbent assay; SLEDAI SLE disease activity index; n number. The data is presented as their mean and standard deviations